Hao Luwen, Chen Xin, Zhou Sijia, Hu Xuemei, Hu Daoyu, Li Zhen, Shen Yaqi
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Radiology, Taikang Tongji (Wuhan) Hospital, Wuhan, China.
Quant Imaging Med Surg. 2025 Sep 1;15(9):7774-7787. doi: 10.21037/qims-24-2033. Epub 2025 Aug 19.
Intraoperative intraperitoneal chemotherapy using sustained-release fluorouracil implants has been used to reduce the recurrence of gastrointestinal tumors. However, these implants may persist and present as tumor-like lesions in imaging studies, potentially leading to false-positive interpretations as metastatic sites, affecting patient management. Our study aimed to enhance the diagnostic accuracy of radiologists in assessing gastric and colorectal cancer patients with fluorouracil implants.
This retrospective study comprised a summary of fluorouracil implant-related lesion characteristics by a multidisciplinary team (MDT), and a three-stage evaluation of tumor-like lesions by two radiologists. In total, 240 computed tomography (CT) examinations were randomly selected from all the available CT examinations of all patients, whom were then further divided evenly into three groups. Two radiologists independently assessed the implant-related tumor-like lesions across the following three stages: stage 1: pre-training without surgical information; stage 2: post-training without surgical information; and stage 3: post-training with surgical details provided. The training was based on the characteristics of the lesions identified earlier by the MDT. The radiologists evaluated the malignancy or benignity of each lesion, and rated their diagnostic confidence using a three-point scale. The reference standard was determined by the MDT. Diagnostic accuracy and diagnostic confidence were compared using Pearson's Chi-squared test and the Wilcoxon rank-sum test.
A total of 168 fluorouracil implants were confirmed in the subdiaphragmatic regions, paracolic gutters, and tumor beds of 164 patients. Imaging features such as a typical foreign body reaction (85.71%), no contrast enhancement on CT/magnetic resonance imaging, and no diffusion restriction on diffusion-weighted imaging were important for differentiating between fluorouracil implant-related lesions and malignant lesions. Follow-up CT scans showed a size reduction in 67.26% of the lesions and density changes in 52.98%. The diagnostic accuracy and confidence of the radiologists were improved in stage 2 (accuracy: 91.25%; confidence: most often classified as medium) compared to stage 1 (accuracy: 67.5%; confidence: most often classified as low; both P<0.001). When surgical information was available, the diagnostic accuracy and confidence of the radiologists were improved in stage 3 (accuracy: 100%; confidence most often classified as high) compared to stage 2 (accuracy: P=0.007; confidence: P<0.001).
The diagnostic accuracy and confidence of radiologists can be improved by providing them with training on implant imaging characteristics and precise surgical record documentation on the implant location and quantity.
使用缓释氟尿嘧啶植入物进行术中腹腔内化疗已被用于降低胃肠道肿瘤的复发率。然而,这些植入物可能会持续存在,并在影像学检查中表现为肿瘤样病变,可能导致将其误诊为转移灶的假阳性结果,从而影响患者的治疗管理。我们的研究旨在提高放射科医生对接受氟尿嘧啶植入物治疗的胃癌和结直肠癌患者的诊断准确性。
这项回顾性研究包括一个多学科团队(MDT)对氟尿嘧啶植入物相关病变特征的总结,以及两名放射科医生对肿瘤样病变的三阶段评估。从所有患者的所有可用CT检查中随机选择240例CT检查,然后将这些患者平均分为三组。两名放射科医生在以下三个阶段独立评估与植入物相关的肿瘤样病变:第1阶段:无手术信息的预培训阶段;第2阶段:无手术信息的培训后阶段;第3阶段:提供手术细节的培训后阶段。培训基于MDT先前确定的病变特征。放射科医生评估每个病变的恶性或良性,并使用三点量表对他们的诊断信心进行评分。参考标准由MDT确定。使用Pearson卡方检验和Wilcoxon秩和检验比较诊断准确性和诊断信心。
在164例患者的膈下区域、结肠旁沟和肿瘤床中共确认了168个氟尿嘧啶植入物。典型的异物反应(85.71%)、CT/磁共振成像上无对比增强以及扩散加权成像上无扩散受限等影像学特征对于区分氟尿嘧啶植入物相关病变和恶性病变很重要。随访CT扫描显示67.26%的病变大小减小,52.98%的病变密度改变。与第1阶段(准确性:67.5%;信心:最常分类为低;P均<0.001)相比,放射科医生在第2阶段的诊断准确性和信心有所提高(准确性:91.25%;信心:最常分类为中等)。当有手术信息时,与第2阶段相比,放射科医生在第3阶段的诊断准确性和信心有所提高(准确性:100%;信心最常分类为高)(准确性:P = 0.007;信心:P<0.001)。
通过为放射科医生提供关于植入物成像特征的培训以及关于植入物位置和数量的精确手术记录文档,可以提高他们的诊断准确性和信心。